Developer docs
API playgroundTry for free, no card

Search company profiles

Valinor Pharma

Full company profile

uuid000aqtf

Namestring
Valinor Pharma
Legal namestring
Valinor Pharma, LLC
Websiteurl
valinorrx.com
Company typeenum
Private
Founded yearstring
-
Short descriptiontext

Valinor Pharma was a Canada-based specialty pharmaceutical company developing non-opioid pain management therapies and advanced pain patch drug delivery systems. It was acquired by Germany's Grünenthal for $250 million in July 2024 and rebranded as Averitas Pharma Inc. in October 2025.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersChicago, United States
HQ citystring
Chicago
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
pain management therapies, non-opioid pharmaceuticals, pain patch drug delivery, pharmaceutical commercialization, advanced drug delivery systems
Industry2 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pain Management Pharmaceuticals
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Valinor Pharma developed and commercialized pain management therapies with a focus on non-opioid alternatives and unmet medical needs in pain care. Its core product centered on a pain patch utilizing an advanced drug delivery system designed for self-administered, home-based pain treatment.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Pain Management Therapies
CategoryPain Management Pharmaceuticals
Description

Valinor Pharma's core offering consisted of non-opioid pain management therapies delivered through a proprietary pain patch using an advanced drug delivery system. The therapies were designed for patients requiring pain management solutions and for healthcare providers seeking non-opioid alternatives to address unmet medical needs in pain therapy.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Valinor Pharma

Pain Management Pharmaceuticalsvalinorrx.com

Valinor Pharma was a Canada-based specialty pharmaceutical company developing non-opioid pain management therapies and advanced pain patch drug delivery systems. It was acquired by Germany's Grünenthal for $250 million in July 2024 and rebranded as Averitas Pharma Inc. in October 2025.

Valinor Pharma firmographics

Firmographics
Name
Valinor Pharma
Legal name
Valinor Pharma, LLC
Website
https://valinorrx.com
Company type
Private
Operating status
Acquired
Headcount range
11–50 employees
Short description
Valinor Pharma was a Canada-based specialty pharmaceutical company developing non-opioid pain management therapies and advanced pain patch drug delivery systems. It was acquired by Germany's Grünenthal for $250 million in July 2024 and rebranded as Averitas Pharma Inc. in October 2025.
Ownership category
akta.pro rank

Valinor Pharma industry classification

Industry
Product category
Pain Management Pharmaceuticals
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIADAA
Pain Relief & Anti-Inflammatory (Analgesics)
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Pain management therapies
  • Non-opioid pharmaceuticals
  • Pain patch drug delivery
  • Pharmaceutical commercialization
  • Advanced drug delivery systems

Where Valinor Pharma is headquartered

Location

Headquarters

HQ city
Chicago
HQ country
United States
HQ region
North America

Markets served

Valinor Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Valinor Pharma product offering

Product offering

Core offering

Valinor Pharma developed and commercialized pain management therapies with a focus on non-opioid alternatives and unmet medical needs in pain care. Its core product centered on a pain patch utilizing an advanced drug delivery system designed for self-administered, home-based pain treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pain Management Therapies Valinor Pharma's core offering consisted of non-opioid pain management therapies delivered through a proprietary pain patch using an advanced drug delivery system. The therapies were designed for patients requiring pain management solutions and for healthcare providers seeking non-opioid alternatives to address unmet medical needs in pain therapy.

Companies that use Valinor Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

Valinor Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Valinor Pharma partnerships and signals

Strategic signal

Scale indicators1 record

Valinor Pharma competitors and assessment

Company assessment

Market position

Customer concentration

Valinor Pharma social profiles

Digital presence

Valinor Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Valinor Pharma leadership team

Management profile

Number of profiles

Valinor Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Valinor Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valinor Pharma

What does Valinor Pharma do?

Valinor Pharma developed and commercialized pain management therapies with a focus on non-opioid alternatives and unmet medical needs in pain care. Its core product centered on a pain patch utilizing an advanced drug delivery system designed for self-administered, home-based pain treatment.

Is Valinor Pharma a public or private company?

Valinor Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was Valinor Pharma founded?

Valinor Pharma was founded in -1. It employs 11 to 50 people.

Where is Valinor Pharma based?

Valinor Pharma is headquartered in Chicago, United States, in the North America region.

Does Valinor Pharma have an API?

No public API is recorded for Valinor Pharma.

What industry is Valinor Pharma in?

Valinor Pharma's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIADAA, Pain Relief & Anti-Inflammatory (Analgesics). Its NAICS code is 3391 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comGlobal Factors Driving the Rapid Evolution of the Pain Patch MarketThe pain patch market is projected to grow from its current valuation to $6.29 billion by 2030, reflecting a compound annual growth rate of 7.3%, driven by demand for non-opioid alternatives, advanced drug delivery systems, and self-administered pain treatments. In July 2024, Germany's Grünenthal acquired Canada-based Valinor Pharma for $250 million to strengthen its position in pain management and develop therapies for unmet medical needs. The market report identifies key trends including the rise of reusable patches, microneedle technology adoption, and expansion of home-based pain care.PR NewswireКомпания Grünenthal приобретает Valinor Pharma за общую сумму около 250 млн долларовGrünenthal has acquired Valinor Pharma for approximately $250 million in cash, gaining global rights to the drug Movantik (naloxegol). Valinor, which had owned the Movantik rights since early 2023, used the Apollo Care commercial platform to boost U.S. sales, reducing gross-to-net gaps and operating expenses. First-quarter 2024 results showed net revenue up 150% year-over-year and the highest EBITDA margin in the company's history.PR NewswireValinor Pharma oznamuje akvizíciu spoločnosťou Grünenthal v celkovej hodnote približne 250 miliónov USDGrünenthal acquired Valinor Pharma in an all-cash transaction valued at approximately $250 million, gaining global rights to the pharmaceutical product Movantik (naloxegol). Valinor had owned Movantik since early 2023 and transformed its commercial performance, achieving 150% revenue growth in Q1 2024 compared to Q1 2023, along with record EBITDA. The acquisition recognizes the value Valinor built through its commercial platform Apollo Care, which helped reduce gross-to-net costs while increasing prescriptions in the US market.PR NewswireValinor Pharma annonce son acquisition par Grünenthal pour une valeur totale d'environ 250 millions de dollarsGrünenthal has acquired Valinor Pharma for approximately $250 million in an all-share transaction, gaining worldwide rights to Movantik® (naloxegol). Under Valinor's ownership since early 2023, Movantik experienced a turnaround with Q1 2024 net revenues growing 150% compared to Q1 2023, alongside record EBITDA. The acquisition provides Grünenthal with Valinor's commercial platform built in partnership with Apollo Care, designed to optimize patient access and reduce gross and net costs.PR NewswireValinor Pharma kündigt Übernahme durch Grünenthal mit einem Gesamtwert von ca. 250 Millionen US-Dollar anGrünenthal has agreed to acquire Valinor Pharma for approximately $250 million, securing worldwide rights to the drug Movantik (naloxegol). This acquisition follows a period of significant growth for Valinor, which reported a 150% increase in net revenue and record EBITDA in Q1 2024 after partnering with Apollo Care. The deal marks the end of Valinor's ownership of Movantik since early 2023, during which time they successfully reversed declining prescription trends.PR NewswireValinor Pharma oznamuje akvizici společností Grünenthal v transakci o celkové hodnotě přibližně 250 milionů dolarůGrünenthal has acquired Valinor Pharma in a transaction valued at approximately $250 million, gaining global rights to the drug Movantik. This acquisition follows a period of significant growth for Valinor, which reported a 150% revenue increase and record EBITDA in the first quarter of 2024 after implementing new commercial strategies with Apollo Care.PR NewswireValinor Pharma anuncia su adquisición por parte de GrünenthalGrünenthal acquired Valinor Pharma for approximately $250 million in initial cash consideration, gaining global rights to Movantik® (naloxegol). Valinor, which had owned Movantik since early 2023 and partnered with Apollo Care to commercialize the drug, reported 150% revenue growth in Q1 2024 and its highest-ever EBITDA, reversing a prior decline in Movantik's performance. The transaction recognizes the value created through Valinor's commercial platform and innovative sales and patient access tools./grunenthal groupGrünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®Grünenthal has acquired the US-based pharmaceutical company Valinor Pharma and its product Movantik® for approximately $250 million, becoming the global owner of the brand. This transaction expands Grünenthal's portfolio in the United States, where Movantik® generated over $200 million in gross sales in 2023. The acquisition follows Grünenthal's previous purchase of European rights to the drug in 2023 via a joint venture with Kyowa-Kirin.NewswireValinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 MillionGrünenthal has acquired Valinor Pharma in an all-stock transaction valued at approximately $250 million, securing global rights to the drug Movantik. The deal follows a period of significant growth for Valinor, which reported 150% revenue growth and record EBITDA in Q1 2024 after leveraging Apollo Care's commercial platform. This acquisition allows Grünenthal to integrate Valinor's innovative sales and patient access strategies into its portfolio.